Clinical trial Recruiting at 836 sites Phase 3 Interventional Ages 40 and up

Investigating heart failure treatment with Baxdrostat and Dapagliflozin

Official title: A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death

Run by AstraZeneca · NCT06677060 · Data updated 2026-11-12

This study is testing if a new combination of two medications can help adults over 40 with heart failure, type 2 diabetes, and heart disease feel better and live longer.

More Heart Failure trials Research outlook What's coming for Heart failure: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages40 Years and up
SexAll
Enrollment11300 (estimated)
SponsorAstraZeneca
Industry-sponsored
Locations977 sites (Birmingham, Alabama and 976 other locations)
StatusRecruiting
StartedMarch 14, 2025
Main results expectedDecember 17, 2029
Study endsDecember 17, 2029
Registry record updatedOctober 21, 2026
Trial IDNCT06677060 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include men and women aged 40 and older with type 2 diabetes, established cardiovascular disease, and a history of hypertension.

Probably not a fit

Patients without a diagnosis of type 2 diabetes or those who do not have established cardiovascular disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of Baxdrostat in combination with Dapagliflozin in treating heart failure among adults aged 40 and older with type 2 diabetes and established cardiovascular disease. Participants will undergo a pre-screening period to identify eligibility, followed by a screening phase where they will be assessed for inclusion criteria. Those who qualify will receive either the combination treatment or a placebo alongside Dapagliflozin. The study seeks to determine the impact of this treatment on heart failure and cardiovascular death.

Why it matters

Potential benefit: If successful, this treatment could significantly improve outcomes for patients with heart failure and reduce cardiovascular mortality.

How similar studies have gone: Other studies have shown promising results with similar combinations of treatments for heart failure, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants of any sex and gender must be ≥ 40 years old at the time of signing the informed consent.
* Diagnosed with T2DM and requiring treatment
* Established CV disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease)
* History of HTN and an SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the Randomisation Visit.
* At least one additional risk factor for HF:

  * Age ≥ 70 years
  * UACR \> 20 mg/g
  * eGFR \< 60 mL/min/1.73 m2
  * History of polyvascular disease (at least two of: ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease)
  * History of atrial fibrillation or atrial flutter
  * NT-proBNP \> 125 ng/L

Exclusion Criteria:

* Previously confirmed diagnosis and treatment of heart failure
* An eGFR \< 30 mL/min/1.73 m2 at screening
* Known hyperkalaemia, defined as potassium ≥ 5.5 mmol/L within 3 months prior to screening
* Type 1 diabetes mellitus or uncontrolled T2DM with HbA1c \> 10.5% (\> 91 mmol/mol) at screening
* Serum sodium \< 135 mmol/L at screening, determined as per central laboratory assessment
* Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, carotid angioplasty, or cardiac surgery, within 3 months prior to randomisation
* Myocardial infarction within 3 months prior to randomisation, or within 1 month prior to randomisation when there is no further planned revascularisation
* Percutaneous coronary intervention within 1 month prior to randomisation
* Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history
* Documented history of adrenal insufficiency
* Any dialysis (including for acute kidney injury) within 3 months prior to screening
* Any acute kidney injury within 3 months prior to screening
* Prohibited concomitant medications

Where it's running

  • Research Site
    Birmingham, Alabama, United States
    Recruiting
  • Research Site
    Centreville, Alabama, United States
    Recruiting
  • Research Site
    Fairhope, Alabama, United States
    Recruiting
  • Research Site
    Huntsville, Alabama, United States
    Recruiting
  • Research Site
    Mobile, Alabama, United States
    Recruiting
  • Research Site
    Sheffield, Alabama, United States
    Recruiting
Show 44 more locations
  • Research Site
    Vestavia Hills, Alabama, United States
    Recruiting
  • Research Site
    Gilbert, Arizona, United States
    Recruiting
  • Research Site
    Tempe, Arizona, United States
    Recruiting
  • Research Site
    Tucson, Arizona, United States
    Recruiting
  • Research Site
    Huntington Beach, California, United States
    Recruiting
  • Research Site
    Inglewood, California, United States
    Recruiting
  • Research Site
    La Jolla, California, United States
    Recruiting
  • Research Site
    Lincoln, California, United States
    Recruiting
  • Research Site
    Loma Linda, California, United States
    Recruiting
  • Research Site
    Los Angeles, California, United States
    Recruiting
  • Research Site
    Los Angeles, California, United States
    Recruiting
  • Research Site
    Sacramento, California, United States
    Recruiting
  • Research Site
    San Diego, California, United States
    Recruiting
  • Research Site
    San Dimas, California, United States
    Recruiting
  • Research Site
    San Francisco, California, United States
    Recruiting
  • Research Site
    Santa Maria, California, United States
    Recruiting
  • Research Site
    Thousand Oaks, California, United States
    Recruiting
  • Research Site
    Aurora, Colorado, United States
    Recruiting
  • Research Site
    Englewood, Colorado, United States
    Recruiting
  • Research Site
    Bridgeport, Connecticut, United States
    Recruiting
  • Research Site
    Stamford, Connecticut, United States
    Recruiting
  • Research Site
    Waterbury, Connecticut, United States
    Recruiting
  • Research Site
    Crystal River, Florida, United States
    Recruiting
  • Research Site
    Fort Myers, Florida, United States
    Recruiting
  • Research Site
    Jacksonville, Florida, United States
    Recruiting
  • Research Site
    Lakeland, Florida, United States
    Recruiting
  • Research Site
    Miami, Florida, United States
    Recruiting
  • Research Site
    Miami, Florida, United States
    Recruiting
  • Research Site
    Miami, Florida, United States
    Recruiting
  • Research Site
    Miami Lakes, Florida, United States
    Recruiting
  • Research Site
    Orlando, Florida, United States
    Recruiting
  • Research Site
    Palmetto Bay, Florida, United States
    Recruiting
  • Research Site
    Saint Augustine, Florida, United States
    Recruiting
  • Research Site
    Atlanta, Georgia, United States
    Recruiting
  • Research Site
    Canton, Georgia, United States
    Recruiting
  • Research Site
    Columbus, Georgia, United States
    Recruiting
  • Research Site
    Cordele, Georgia, United States
    Recruiting
  • Research Site
    Suwanee, Georgia, United States
    Recruiting
  • Research Site
    Tucker, Georgia, United States
    Recruiting
  • Research Site
    Woodstock, Georgia, United States
    Recruiting
  • Research Site
    Idaho Falls, Idaho, United States
    Recruiting
  • Research Site
    Champaign, Illinois, United States
    Recruiting
  • Research Site
    Chicago, Illinois, United States
    Recruiting
  • Research Site
    Chicago, Illinois, United States
    Recruiting

+927 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.